Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06601465
PHASE2
COgnitioN With VERiciGuat Evaluation in Heart Failure
Sponsor: University of Alberta
View on ClinicalTrials.gov
Summary
CONVERGE-HF is a 4-center pilot phase IIb randomized control trial in ambulatory patients with chronic heart failure (≥ 6 months) and mild-to-moderate cognitive impairment.
Official title: CONVERGE-HF: COgnitioN With VERiciGuat Evaluation in Heart Failure
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2025-06-03
Completion Date
2027-05
Last Updated
2025-07-31
Healthy Volunteers
No
Conditions
Interventions
DRUG
Vericiguat
Tablet - 2.5 mg, 5 mg, 10 mg
Locations (4)
University of Calgary
Calgary, Alberta, Canada
University of Alberta
Edmonton, Alberta, Canada
University of Ottawa
Ottawa, Ontario, Canada
McGill University Health Center
Montreal, Quebec, Canada